Evaluating the addition of AMG 655 to mFOLFOX6/bevacizumab in metastatic colorectal cancer

Community Oncology

Volumn 5, Issue 10 SUPPL. A, 2008, Pages 1-4

  Fuchs, Charles S ^a   Saltz, Leonard B ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 655; BEVACIZUMAB; DEATH RECEPTOR 5; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLACEBO; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; FATIGUE; FEVER; HIGH RISK PATIENT; HUMAN; HYPOMAGNESEMIA; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; SHORT SURVEY; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 56149104587     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta, Ga: American Cancer Society; 2008. Available at: http://www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf. Accessed September 16, 2008.
2. Gill S, Loprinri CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-1806.
3. US Food and Drug Administration. FDA approves first angiogenesis inhibitor to treat colorectal cancer. February 26, 2004. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html. Accessed September 16, 2008.
4. National Cancer Institute. NCI Drug Dictionary. Anti-TRAIL receptor 2 monoclonal antibody AMG 655. US Institutes of Health. Available at: http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=573083. Accessed September 16, 2008.
5. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-339.
6. Fesik SW. Promoting apoptosis as a drug strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885.
7. Kaplan-Lefko P, Bush T, Belmontes B, et al. AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. Presented at the 2008 Annual Meeting of the American Association for Cancer Research; April 12-16, 2008; San Diego, Calif. Abstract 3999.
8. Coxon A, Rex K, Sun J-R, et al. Combined treatment of angiopoietin and VEGF pathway antagonists enhances antitumor activity in preclinical models of colon carcinoma. Presented at the 2008 Annual Meeting of the American Association for Cancer Research; April 12-16, 2008; San Diego, Calif. Abstract 1113.
9. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 2007;25(18S):3534.